Your session is about to expire
← Back to Search
Behavioural Intervention
Self-Management Program for Spanish Speakers with Epilepsy
N/A
Waitlist Available
Led By Elaine T Kiriakopoulos, MD, MPH, MSc
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Spanish as primary language
Self-reported epilepsy with controlled or uncontrolled seizures
Must not have
No self-reported diagnosis of epilepsy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after the completion of the hobscotch-spanish/espanol program, approximately 9 weeks later.
Awards & highlights
Summary
This trial aims to see if a program called HOBSCOTCH, which helps people manage epilepsy at home, can be translated successfully for Spanish-speaking individuals with epilepsy. Participants will attend nine one-hour
Who is the study for?
This trial is for adults over 18 with epilepsy, who primarily speak Spanish and can read in Spanish. They must have internet or phone access. It's not for those with dementia, severe mental disability (IQ <70), significant visual impairment, or without a self-reported epilepsy diagnosis.
What is being tested?
The study tests if the HOBSCOTCH program—a home-based cognitive training—can be translated effectively into Spanish to help improve quality of life and manage epilepsy symptoms through virtual sessions with a bilingual coach.
What are the potential side effects?
Since this intervention involves educational and self-management strategies rather than medication, traditional side effects are not expected. However, participants may experience discomfort from discussing personal health issues.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
Spanish is my first language.
Select...
I have epilepsy with seizures that may or may not be under control.
Select...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have never been diagnosed with epilepsy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ after the completion of the hobscotch-spanish/espanol program, approximately 9 weeks later.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after the completion of the hobscotch-spanish/espanol program, approximately 9 weeks later.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in quality of life as measured by comparing the pre and post HOBSCOTCH-Spanish/Espanol intervention scores on the Quality of Life in Epilepsy-10 (QOLIE-10).
Change in subjective cognition as measured by comparing the pre and post HOBSCOTCH-Spanish/Espanol intervention scores on NeuroQOL - Cognitive Function sub-scale.
Secondary outcome measures
Evaluation of participants' perception of shared-decision making during HOBSCOTCH-Spanish/Espanol intervention as measured by CollaboRATE score.
Participant satisfaction with the HOBSCOTCH-Spanish/Espanol program as measured by analyzing a Participant Satisfaction Survey at the end of the study.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Spanish speaking participant with self-reported epilepsy and cognitive and memory dysfunctionExperimental Treatment1 Intervention
Participants will receive the HOBSCOTCH intervention (in Spanish) consisting of 1:1 sessions delivered once per week including:
1 pre-HOBSCOTCH Session (on webcam or by phone)
1 educational session (on webcam) 6 HOBSCOTCH intervention sessions (webcam or phone)
1 wrap-up session (webcam or phone)
Find a Location
Who is running the clinical trial?
Dartmouth-Hitchcock Medical CenterLead Sponsor
530 Previous Clinical Trials
2,544,924 Total Patients Enrolled
13 Trials studying Epilepsy
1,174 Patients Enrolled for Epilepsy
Elaine T Kiriakopoulos, MD, MPH, MScPrincipal InvestigatorDartmouth-Health/Dartmouth-Hitchcock, Dartmouth College
3 Previous Clinical Trials
25 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger